- Amgen (NASDAQ:AMGN) is partnering with Massachusetts General Hospital and the Broad Institute to develop treatments for inflammatory bowel disease (IBD), a chronic disorder that affects millions worldwide.
- "IBD treatment options are limited," says Amgen VP of R&D Sean Harper. "We believe this collaboration...will help identify improved treatment options for these patients." (PR)